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Serum of cancer patients often contains high activities of a homoarginine-sensitive isoenzyme of alkaline phosphatase with high electrophoretic mobility, which is present in relatively low activities in sera from most normal persons and persons with benigndisease. In earlier studies of this isoenzyme, in a semi-quantitative assay,
electrophoresis was used in the separation step. This report describes a column separation procedure, which provides quantitative data. We tested the revised procedure by assaying a mixed panel of 192 sera (cancer, benign disease, and normal).
The organ sites of cancer and benign disease in this study were: lung, pancreas, uterus, and ovaries.
The isoenzyr1e showed moderate sensitivity for lung (0.6) and pancreas (0.8) cancer and high specificity for all cancers tested. Thus the assay may be useful for discriminating between cancer sera and non-cancer sera for these cancer types.
We reported the appearance in serum of an electrophoretically fast, homoarginine-sensitive isoenzyme of alkaline phosphatase (EC 3.1.3.1; FHAP) that bears a relationship to the presence of cancer (1) . In the initial studies, we used an electrophoretic separation technique and a semiquantitative assay procedure which were described in detail (2) . A procedure for the column -chromatographic separation of FHAP was described earlier (3). High FHAP values for presumably normal persons, which varied with total alkaline phosphatase concentration, led us to conclude that FHAP was incompletely separated from other serum alkaline phosphatase activity. Here, we describe an improved column separation procedure, together with an analysis of the FHAP activity in a mixed panel of cancer and non-cancer sera provided in a blind manner by the Mayo Clinic Serum Bank.
Materials and Methods

Source of Test Sera
The Mayo Clinic sera were stored frozen for various intervals at -80 #{176}C. They were shipped in solid CO2 and allowed to thaw just before analysis. The sera were analyzed in random order. Those For quality control we used high and normal FHAP "column control" serum samples separated and analyzed with each assay and analyzed a diluted serum secondary standard in each assay. The within-assay CV was 6% for samples be- 
Statistical Methods
Chi square analysis (2 X 2 tables) was used to assess the discrimination power of the assay. The pairs analyzed were: lung cancer vs smokers, pancreatic cancer vs benign disease of the gastrointestinal tract, cancer of the uterus and ovaries vs benign disease of these organs, and all cancers vs all noncancer persons. The sensitivity and specificity, as well as the probability of misclassification, were determined in each of the paired groups.
The Gail--Green procedure (5) was used to locate the optimal cut-off value. This proved to be 2.09 U/L, which was so near the previously accepted value of 2.10 U/L that we used only the latter in the chi square analyses. Table 2 shows the sensitivity and specificity of the test. Sensitivity characterizes the incidence of positive test results, i.e., FHAP scores of 2.10 U/L or above among patients known to have cancer (true positives).
Results
Specificity characterizes the incidence of negative test results, i.e., FHAP scores 2.10 UIL (true negatives) in patients presumed not to have cancer. These two test variables were examined by organ site and as groups. The sensitivity of FHAP for lung cancer was 0.60, for pancreatic cancer, 0.77, and for cancer of the uterus and ovaries (combined) it was 0.43. Because there were no FHAP values 2.10 U/L among the normal or smoker groups, the specificity was 1.0. However, lower values were obtained for benign diseases of the gastrointestinal tract (0.73) and for the benign gynecologic group (0.92). The pooled cancer data were compared with the data for all non-cancer persons, including those with benign disease. The sensitivity of the test was 0.60. The specificity for the normal group was 1.0, while for the combined group it was reduced to 0.91.
The chi-square analysis demonstrated that it was highly unlikely (p <0.0001) that the difference between the groups compared had occurred by chance, except in the case of gynecologic cancer vs benign disease of the female reproductive system, where the probability was <0.069.
Discussion
We Nearly all had had liver scans and many had been autopsied. Table 3 shows the results of this survey. Of 72 patients with cancer in this study, 17 were known to have hepatic metastasis.
Of these, eight had FHAP values less than the cut-off score of 2.1 U/L. Thirtynine had no evidence of metastasis.
Of these, 17 had abovenormal FHAP values. There appears to be no strong relation in our study between increased FHAP and hepatic metastasis. Some correlation might be expected, because we have observed a correlation between serum FHAP concentration and tumor load (unpublished observations). We have considered the possibility that increased FHAP activity is a direct consequence of increased total alkaline phosphatase activity. Our previous studies have not shown a high correlation between these markers. We analyzed the relationship between total alkaline phosphatase and FHAP among the 71 cancer patients in this study for whom total serum alkaline phosphatase values were available. As shown in Table 4 , only 26% of these patients had increases in both markers, an additional 25% had increased FHAP and normal total alkaline phosphatase, 8% had increased total alkaline phosphatase but not FHAP, and 40% had normal values for both markers. A linear regression of FHAP vs total alkaline phosphatase gave a correlation coefficient of 0.49. Thus high FHAP activity is not a direct consequence of high total serum alkaline phosphatase activity.
We conclude that the activity of an alkaline phosphatase enzyme, FHAP, is increased (far more commonly) in the serum of cancer patients than in the serum of normal persons or persons with benign diseases. FHAP can be detected and quantified rapidly by a simple technique involving an ionexchange resin and a fluorometer.
In this study the value of FHAP assay in detecting cancer of the lung, the pancreas, and the female reproductive system was examined. FHAP assay showed a moderate sensitivity for lung and pancreatic cancer (0.6-0.8) and a very high specificity.
The assay seems to have merit for discriminating between cancer and non-cancer sera for certain types of cancer.
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